Alzheimer’s Disease Targeted Nano-Based Drug Delivery Systems

(E-pub Ahead of Print)

Author(s): Gülcem Altinoglu, Terin Adali*.

Journal Name: Current Drug Targets

Become EABM
Become Reviewer


Alzheimer’s disease (AD) is the most common neurodegenerative disease, and is part of a massive and growing health care burden that is destroying the cognitive function of more than 50 million individuals worldwide. Today, therapeutic options are limited to approaches with mild symptomatic benefits. The failure in developing effective drugs is attributed to, but not limited to the highly heterogeneous nature of AD with multiple underlying hypotheses and multifactorial pathology. In addition, targeted drug delivery to the central nervous system (CNS), for the diagnosis and therapy of neurological diseases like AD, is restricted by the challenges posed by blood-brain interfaces surrounding the CNS, limiting the bioavailability of therapeutics. Research done over the last decade has focused on developing new strategies to overcome these limitations and successfully deliver drugs to the CNS. Nanoparticles, that are capable of encapsulating drugs with sustained drug release profiles and adjustable physiochemical properties, can cross the protective barriers surrounding the CNS. Thus, nanotechnology offers new hope for AD treatment as a strong alternative to conventional drug delivery mechanisms. In this review, potential application of nanoparticle based approaches in Alzheimer’s disease and their implications in therapy is discussed.

Keywords: Alzheimer’s disease, nanoparticles, nanotechnology, drug delivery, targeted delivery

Rights & PermissionsPrintExport Cite as

Article Details

(E-pub Ahead of Print)
DOI: 10.2174/1389450120666191118123151
Price: $95

Article Metrics

PDF: 9